ONCE Spark Therapeutics, Inc.

52.41
0  -1%
Previous Close 52.82
Open 52.77
Price To book 4.94
Market Cap 1.63B
Shares 31,044,000
Volume 178,787
Short Ratio 14.76
Av. Daily Volume 345,457

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 4Q 2016 with initial data due mid 2017.
SPK-8011
Hemophilia A
Phase 1/2 updated data at ASH 2016. Further update due 1H 2017.
SPK-9001
Hemophilia B
Phase 1/2 dosing commenced 1Q 2015. Initial data due early 2017.
SPK-7001 (SPK-CHM)
Choroideremia
BLA filing due early 2017.
SPK-RPE65
Inherited retinal dystrophies

Latest News

  1. Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  2. 3 Biotech Stocks to Buy in March
  3. SPARK THERAPEUTICS, INC. Financials
  4. 5 Small-Cap Biotech Stocks to Buy in March
  5. Spark Therapeutics to Participate in Multiple Conferences in March
  6. Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency
  7. SPARK THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
  8. Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: 2016 By the Numbers : February 24, 2017
  9. Edited Transcript of ONCE earnings conference call or presentation 22-Feb-17 1:30pm GMT
  10. Why Spark's CEO says 2017 may be a 'historic year' for his gene therapy company
  11. SPARK THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  12. Spark Therapeutics Reports 2016 Financial Results and Business Highlights
  13. Spark Therapeutics to Host Conference Call on Wednesday, Feb. 22 at 8:30 a.m. to Discuss 2016 Results
  14. Coverage initiated on Spark Therapeutics by Leerink Partners
  15. Spark Therapeutics to Participate in Multiple February Conferences
  16. Spark Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ONCE-US : January 18, 2017
  17. Spark Therapeutics Announces U.S. Orphan Drug Designation Amendment and Study Updates for Lead Investigational Gene Therapy
  18. Spark Gets A Check From Pfizer And A Downgrade From Vetr
  19. Spark Therapeutics, Inc. – Value Analysis (NASDAQ:ONCE) : January 5, 2017
  20. Company News for January 05, 2017